Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ

$8.69 0.27 (3.21%)

Market Cap: $1.19B

As of 08/15/22 12:35 PM EDT. Market open.

(AUPH)

Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ

$8.69 0.27 (3.21%)

Market Cap: $1.19B

As of 08/15/22 12:35 PM EDT. Market open.

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts ... read more

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Peter Greenleaf
Full Time Employees
294
URL
Address
1203-4464 Markham St, British Columbia, Victoria, V8Z 7X8.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
CEO
Peter Greenleaf
Full Time Employees
294
Address
1203-4464 Markham St, British Columbia, Victoria, V8Z 7X8.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$8.36
Previous Close
$8.42
Days Range
$8.23 - $8.45
52 week range
$7.70 - $33.97
Volume
927,397
Avg. Volume (30 days)
3,104,797
Market Cap
$1.19B
Dividend Yield
0.00%
P/E
-
Shares Outstanding
141,892,181
Open
$8.36
Previous Close
$8.42
Days Range
$8.23 - $8.45
52 week range
$7.70 - $33.97
Volume
927,397
Avg. Volume (30 days)
3,104,797
Market Cap
$1.19B
Dividend Yield
0.00%
P/E
-
Shares Outstanding
141,892,181

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR AURINIA PHARMACEUTICALS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Jayne David R.W. Director May 18, 2022 Option Exercise $3.62 10,000 36,200 40,000 Jul 11, 2022, 06:16 AM
MacKay-Dunn R. Hector Director Mar 09, 2022 Buy $11.00 5,000 54,985 11,000 Mar 11, 2022, 04:05 PM
MILNE GEORGE M JR Director Mar 04, 2022 Buy $10.82 5,000 54,100 50,000 Mar 08, 2022, 04:06 PM
Martin Michael Robert Chief Business Officer Mar 02, 2022 Sale $12.01 4,849 58,236 59,512 Mar 04, 2022, 04:13 PM
Donley Matthew Maxwell Ex VP, Intern'l Operations Mar 02, 2022 Sale $12.01 3,052 36,655 16,224 Mar 04, 2022, 04:12 PM
Miller Joseph M Chief Financial Officer Mar 02, 2022 Sale $12.01 3,060 36,751 6,610 Mar 04, 2022, 04:12 PM
Colao Massimilano Chief Commercial Officer Mar 02, 2022 Sale $12.01 3,205 38,492 13,495 Mar 04, 2022, 04:11 PM
Greenleaf Peter Chief Executive Officer Mar 02, 2022 Sale $12.01 9,068 108,907 32,967 Mar 04, 2022, 04:11 PM
Solomons Neil Chief Medical Officer Mar 02, 2022 Sale $12.01 4,846 58,200 90,953 Mar 04, 2022, 04:10 PM
Huizinga Robert Bindert EVP of Research Mar 02, 2022 Sale $12.01 4,849 58,236 69,379 Mar 04, 2022, 04:10 PM
Leversage Jill Director Dec 13, 2021 Buy $20.04 1,600 32,064 5,300 Dec 15, 2021, 04:09 PM
Martin Michael Robert Chief Business Officer Nov 11, 2021 Option Exercise $18.38 29,000 533,020 95,861 Nov 12, 2021, 04:18 PM
Martin Michael Robert Chief Business Officer Nov 10, 2021 Sale $31.14 60,000 1,868,500 76,861 Nov 12, 2021, 04:18 PM
Martin Michael Robert Chief Business Officer Nov 09, 2021 Sale $30.17 50,000 1,508,500 126,861 Nov 12, 2021, 04:18 PM
Martin Michael Robert Chief Business Officer Nov 11, 2021 Sale $29.01 40,000 1,160,280 66,861 Nov 12, 2021, 04:18 PM
Solomons Neil Chief Medical Officer Nov 10, 2021 Option Exercise $5.83 100,000 583,200 187,299 Nov 12, 2021, 04:13 PM
Solomons Neil Chief Medical Officer Nov 11, 2021 Option Exercise $5.30 100,000 530,000 187,299 Nov 12, 2021, 04:13 PM
Solomons Neil Chief Medical Officer Nov 09, 2021 Sale $30.17 50,000 1,508,500 87,299 Nov 12, 2021, 04:13 PM
Solomons Neil Chief Medical Officer Nov 11, 2021 Sale $28.89 100,000 2,889,000 87,299 Nov 12, 2021, 04:13 PM
Solomons Neil Chief Medical Officer Nov 10, 2021 Sale $31.11 100,000 3,110,800 97,299 Nov 12, 2021, 04:13 PM
Solomons Neil Chief Medical Officer Nov 01, 2021 Option Exercise $5.30 45,000 238,500 182,299 Nov 03, 2021, 04:24 PM
Solomons Neil Chief Medical Officer Nov 01, 2021 Sale $31.64 45,000 1,423,800 137,299 Nov 03, 2021, 04:24 PM
Martin Michael Robert Chief Business Officer Nov 01, 2021 Option Exercise $3.20 45,000 144,000 221,861 Nov 03, 2021, 04:20 PM
Martin Michael Robert Chief Business Officer Nov 01, 2021 Sale $31.64 45,000 1,423,800 176,861 Nov 03, 2021, 04:20 PM
Huizinga Robert Bindert EVP of Research Oct 25, 2021 Option Exercise $3.20 95,000 304,000 195,728 Oct 26, 2021, 04:33 PM
Huizinga Robert Bindert EVP of Research Oct 25, 2021 Sale $29.75 130,000 3,867,500 65,728 Oct 26, 2021, 04:33 PM
Huizinga Robert Bindert EVP of Research Sep 21, 2021 Option Exercise $2.86 27,136 77,715 133,228 Sep 22, 2021, 04:53 PM
Huizinga Robert Bindert EVP of Research Sep 21, 2021 Sale $23.99 32,500 779,533 106,092 Sep 22, 2021, 04:53 PM
Martin Michael Robert Chief Business Officer Sep 21, 2021 Option Exercise $7.40 87,500 647,750 264,361 Sep 22, 2021, 04:31 PM
Martin Michael Robert Chief Business Officer Sep 20, 2021 Option Exercise $5.30 28,500 151,050 205,361 Sep 22, 2021, 04:31 PM
Martin Michael Robert Chief Business Officer Sep 20, 2021 Sale $21.65 28,500 616,975 192,861 Sep 22, 2021, 04:31 PM
Martin Michael Robert Chief Business Officer Sep 21, 2021 Sale $24.02 87,500 2,101,750 176,861 Sep 22, 2021, 04:31 PM
Martin Michael Robert Chief Business Officer Sep 14, 2021 Option Exercise $5.30 44,000 233,200 220,861 Sep 16, 2021, 05:01 PM
Martin Michael Robert Chief Business Officer Sep 14, 2021 Sale $21.78 44,000 958,220 206,861 Sep 16, 2021, 05:01 PM
Martin Michael Robert Chief Business Officer Sep 14, 2021 Option Exercise $4.25 90,000 382,500 266,861 Sep 14, 2021, 06:16 PM
Martin Michael Robert Chief Business Officer Sep 13, 2021 Option Exercise $5.30 25,000 132,500 201,861 Sep 14, 2021, 06:16 PM
Martin Michael Robert Chief Business Officer Sep 14, 2021 Sale $21.19 90,000 1,907,217 176,861 Sep 14, 2021, 06:16 PM
Martin Michael Robert Chief Business Officer Sep 10, 2021 Sale $19.80 25,000 495,000 176,861 Sep 14, 2021, 06:16 PM
Huizinga Robert Bindert EVP of Research Sep 14, 2021 Sale $21.75 22,500 489,375 106,092 Sep 14, 2021, 05:12 PM
Huizinga Robert Bindert EVP of Research Sep 10, 2021 Sale $19.80 10,000 197,950 133,592 Sep 14, 2021, 05:12 PM
Solomons Neil Chief Medical Officer Sep 13, 2021 Option Exercise $3.20 150,000 480,000 287,299 Sep 14, 2021, 05:11 PM
Solomons Neil Chief Medical Officer Sep 10, 2021 Sale $19.84 150,000 2,976,000 137,299 Sep 14, 2021, 05:11 PM
Martin Michael Robert Chief Business Officer Sep 07, 2021 Sale $18.10 7,500 135,750 176,861 Sep 08, 2021, 04:04 PM
Huizinga Robert Bindert EVP of Research Sep 07, 2021 Sale $18.30 5,000 91,500 138,592 Sep 08, 2021, 04:03 PM
Martin Michael Robert Chief Business Officer Aug 26, 2021 Sale $17.81 22,500 400,725 184,361 Aug 27, 2021, 04:09 PM
Solomons Neil Chief Medical Officer Aug 25, 2021 Sale $15.85 5,000 79,250 137,299 Aug 26, 2021, 04:15 PM
Solomons Neil Chief Medical Officer Aug 09, 2021 Sale $16.03 45,000 721,350 142,299 Aug 10, 2021, 04:11 PM
Martin Michael Robert Chief Business Officer Aug 09, 2021 Sale $16.01 5,000 80,050 206,861 Aug 10, 2021, 04:09 PM
Martin Michael Robert Chief Business Officer Jul 28, 2021 Sale $13.86 5,000 69,300 211,861 Jul 29, 2021, 04:09 PM
Martin Michael Robert Chief Business Officer Jun 22, 2021 Sale $13.76 5,000 68,800 216,861 Jun 23, 2021, 04:06 PM
Donley Matthew Maxwell Ex VP, Intern'l Operations May 11, 2021 Buy $10.07 9,900 99,739 9,900 May 12, 2021, 04:34 PM
Greenleaf Peter Chief Executive Officer May 11, 2021 Buy $10.71 5,125 54,891 13,453 May 12, 2021, 04:32 PM
Solomons Neil Chief Medical Officer Mar 12, 2021 Option Exercise $3.02 40,000 120,800 227,299 Mar 15, 2021, 04:36 PM
Solomons Neil Chief Medical Officer Mar 12, 2021 Sale $13.49 40,000 539,600 187,299 Mar 15, 2021, 04:36 PM
MILNE GEORGE M JR Director Mar 05, 2021 Buy $13.00 5,000 65,000 45,000 Mar 09, 2021, 04:25 PM
Leversage Jill Director Jan 29, 2021 Buy $16.03 400 6,412 400 Feb 02, 2021, 03:22 PM
Leversage Jill Director Jan 29, 2021 Buy $16.03 1,200 19,236 1,200 Feb 02, 2021, 03:22 PM
Hayden Michael R Director Jan 29, 2021 Option Exercise $5.79 95,000 550,100 95,000 Feb 02, 2021, 03:18 PM
Robertson Stephen P. EVP, General Counsel Jan 28, 2021 Buy $16.14 900 14,526 2,720 Jan 29, 2021, 12:24 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Jayne David R.W. Director 05/18/2022 36,200
MacKay-Dunn R. Hector Director 03/09/2022 54,985
MILNE GEORGE M JR Director 03/04/2022 54,100
Martin Michael Robert Chief Business Officer 03/02/2022 58,236
Donley Matthew Maxwell Ex VP, Intern'l Operations 03/02/2022 36,655
Miller Joseph M Chief Financial Officer 03/02/2022 36,751
Colao Massimilano Chief Commercial Officer 03/02/2022 38,492
Greenleaf Peter Chief Executive Officer 03/02/2022 108,907
Solomons Neil Chief Medical Officer 03/02/2022 58,200
Huizinga Robert Bindert EVP of Research 03/02/2022 58,236
Leversage Jill Director 12/13/2021 32,064
Martin Michael Robert Chief Business Officer 11/11/2021 533,020
Martin Michael Robert Chief Business Officer 11/10/2021 1,868,500
Martin Michael Robert Chief Business Officer 11/09/2021 1,508,500
Martin Michael Robert Chief Business Officer 11/11/2021 1,160,280
Solomons Neil Chief Medical Officer 11/10/2021 583,200
Solomons Neil Chief Medical Officer 11/11/2021 530,000
Solomons Neil Chief Medical Officer 11/09/2021 1,508,500
Solomons Neil Chief Medical Officer 11/11/2021 2,889,000
Solomons Neil Chief Medical Officer 11/10/2021 3,110,800
Solomons Neil Chief Medical Officer 11/01/2021 238,500
Solomons Neil Chief Medical Officer 11/01/2021 1,423,800
Martin Michael Robert Chief Business Officer 11/01/2021 144,000
Martin Michael Robert Chief Business Officer 11/01/2021 1,423,800
Huizinga Robert Bindert EVP of Research 10/25/2021 304,000
Huizinga Robert Bindert EVP of Research 10/25/2021 3,867,500
Huizinga Robert Bindert EVP of Research 09/21/2021 77,715
Huizinga Robert Bindert EVP of Research 09/21/2021 779,533
Martin Michael Robert Chief Business Officer 09/21/2021 647,750
Martin Michael Robert Chief Business Officer 09/20/2021 151,050
Martin Michael Robert Chief Business Officer 09/20/2021 616,975
Martin Michael Robert Chief Business Officer 09/21/2021 2,101,750
Martin Michael Robert Chief Business Officer 09/14/2021 233,200
Martin Michael Robert Chief Business Officer 09/14/2021 958,220
Martin Michael Robert Chief Business Officer 09/14/2021 382,500
Martin Michael Robert Chief Business Officer 09/13/2021 132,500
Martin Michael Robert Chief Business Officer 09/14/2021 1,907,217
Martin Michael Robert Chief Business Officer 09/10/2021 495,000
Huizinga Robert Bindert EVP of Research 09/14/2021 489,375
Huizinga Robert Bindert EVP of Research 09/10/2021 197,950
Solomons Neil Chief Medical Officer 09/13/2021 480,000
Solomons Neil Chief Medical Officer 09/10/2021 2,976,000
Martin Michael Robert Chief Business Officer 09/07/2021 135,750
Huizinga Robert Bindert EVP of Research 09/07/2021 91,500
Martin Michael Robert Chief Business Officer 08/26/2021 400,725
Solomons Neil Chief Medical Officer 08/25/2021 79,250
Solomons Neil Chief Medical Officer 08/09/2021 721,350
Martin Michael Robert Chief Business Officer 08/09/2021 80,050
Martin Michael Robert Chief Business Officer 07/28/2021 69,300
Martin Michael Robert Chief Business Officer 06/22/2021 68,800
Donley Matthew Maxwell Ex VP, Intern'l Operations 05/11/2021 99,739
Greenleaf Peter Chief Executive Officer 05/11/2021 54,891
Solomons Neil Chief Medical Officer 03/12/2021 120,800
Solomons Neil Chief Medical Officer 03/12/2021 539,600
MILNE GEORGE M JR Director 03/05/2021 65,000
Leversage Jill Director 01/29/2021 6,412
Leversage Jill Director 01/29/2021 19,236
Hayden Michael R Director 01/29/2021 550,100
Robertson Stephen P. EVP, General Counsel 01/28/2021 14,526
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
06/30/2022
03/31/2022
0.04%
1Q
06/30/2022
12/31/2021
9.56%
2Q
06/30/2022
09/30/2021
10.66%
3Q
06/30/2022
06/30/2021
10.89%
4Q
06/30/2022
03/31/2021
11.25%
5Q
Load More

Period of Report: 06/30/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
03/31/2022
0.04%
1Q
12/31/2021
9.56%
2Q
09/30/2021
10.66%
3Q
06/30/2021
10.89%
4Q
03/31/2021
11.25%
5Q
Load More